Hostname: page-component-848d4c4894-wg55d Total loading time: 0 Render date: 2024-05-29T09:07:10.577Z Has data issue: false hasContentIssue false

Regain of visuospatial capacity after coenzyme Q10 in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes: a case report

Published online by Cambridge University Press:  24 June 2014

Che-Sheng Chu
Affiliation:
Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
Chin-Liang Chu
Affiliation:
Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
Hong-Ern Liu
Affiliation:
Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
Ti Lu*
Affiliation:
Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
*
Ti Lu, Department of Psychiatry, Kaohsiung Veterans General Hospital, No. 386, Ta-Chung1st Road, Kaohsiung 813, Taiwan. Tel: +88673422121x7093; Fax: +88673468346; E-mail: youngtzuchi@hotmail.com

Abstract

Objective: MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) is a neurodegenerative disorder caused by mitochondrial dysfunction. Multiple systems of the body, including cognitive function and heart conduction, can be affected by this disorder. We report a case with global cognitive impairment.

Method: A single-case report.

Results: The patient got improved cognitive function, especially visuospatial function, under coenzyme Q10 treatment.

Conclusion: First, coenzyme Q10 may give some benefit to control MELAS. Second, cognitive functions and intellectual abilities decline with disease progression. Routine neuropsychological tests should be performed.

Type
Case Reports
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Pavlakis, SG, Phillips, PC, DiMauro, S et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol 1984;16:481488.CrossRefGoogle ScholarPubMed
2.Shapira, Y.Clinical aspects of mitochondrial encephalomyopathies. International Pediatrics 1993;8:225232.Google Scholar
3.Goto, Y, Nonaka, I, Horai, S.A mutation in the tRNALeu (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990;348:651653.CrossRefGoogle ScholarPubMed
4.Finsterer, J.Mitochondrial disorders, cognitive impairment and dementia. J Neurol Sci 2009;283:143148.CrossRefGoogle ScholarPubMed
5.Turconi, AC, Benti, R, Castelli, E et al. Focal cognitive impairment in mitochondrial encephalomyopathies: a neuropsychological and neuroimaging study. J Neurol Sci 1999;170:5763.CrossRefGoogle ScholarPubMed
6.Remes, AM, Liimatta, EV, Winqvist, S et al. Ubiquinone and nicotinamide treatment of patients with the 3243A->G mtDNA mutation. Neurology 2002;59:12751277.CrossRefGoogle ScholarPubMed
7.Shinkai, T, Nakashima, M, Ohmori, O et al. Coenzyme Q10 improves psychiatric symptoms in adult-onset mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes: a case report. Aust N Z J Psychiatry 2000;34:10341035.CrossRefGoogle ScholarPubMed
8.Goda, S, Hamada, T, Ishimoto, S et al. Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol 1987;234:6263.CrossRefGoogle Scholar
9.Abe, K, Fujimura, H, Nishikawa, Y et al. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol Scand 1991;83:356359.CrossRefGoogle Scholar
10.Ihara, Y, Namba, R, Kuroda, S et al. Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. J Neurol Sci 1989;90:263271.CrossRefGoogle ScholarPubMed
11.Staub, F, Mackert, B, Kempski, O, Peters, J, Baethmann, A.Swelling and death of neuronal cells by lactic acid. J Neurol Sci 1993;119:7984.CrossRefGoogle ScholarPubMed
12.Kaufmann, P, Shungu, DC, Sano, MC et al. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 2004;62:12971302.CrossRefGoogle ScholarPubMed
13.Berbel-Garcia, A, Barbera-Farre, JR, Etessam, JP et al. Coenzyme Q 10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin Neuropharmacol 2004;27:187191.CrossRefGoogle Scholar
14.Abe, K, Fujimura, H, Nishikawa, Y et al. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol Scand 1991;83:356359.CrossRefGoogle Scholar
15.Finsterer, J.Overview on visceral manifestations of mitochondrial disorders. Neth J Med 2006;64:6171.Google ScholarPubMed
16.Neustadt, J, Pieczenik, SR.Medication-induced mitochondrial damage and disease. Mol Nutr Food Res 2008;52:780788.CrossRefGoogle ScholarPubMed
17.Baik, R, Chae, JH, Lee, YM, Kang, HC, Lee, JS, Kim, HD.Electrocardiography as an early cardiac screening test in children with mitochondrial disease. Korean J Pediatr 2010;53:644647.CrossRefGoogle ScholarPubMed
18.Matthews, PM, Ford, B, Dandurand, RJ et al. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993;43:884890.CrossRefGoogle ScholarPubMed